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Abstract 
There is much evidence that diabetes mellitus (DM) –induced hyperglycemia (HG) is responsible 
for kidney failure or nephropathy leading to cardiovascular complications. Cellular and 
molecular mechanism(s) whereby DM can damage the kidney is still not fully understood. This 
study investigated the effect of streptozotocin (STZ)-induced diabetes (T1DM) on the structure 
and associated molecular alterations of the isolated rat left kidney following 2 and 4 months of 
the disorder compared to the respective age-matched controls. The results revealed 
hypertrophy and general disorganized architecture of the kidney characterized by expansion in 
glomerular borders, tubular atrophy and increased vacuolization of renal tubular epithelial cells 
in the diabetic groups compared to controls. Electron microscopic analysis revealed 
ultrastructural alterations in the left kidney highlighted by an increase in glomerular basement 
membrane width. In addition, increased caspase-3 immuno-reactivity was observed in the 
kidney of T1DM animals compared to age-matched controls.  These structural changes were 
associated with elevated extracellular matrix (ECM) deposition and consequently, altered gene 
expression profile of ECM key components, together with elevated levels of key mediators 
(MMP9, integrin 5α, TIMP4, CTGF, vimentin) and reduced expressions of Cx43 and MMP2 of the 
ECM. Marked hypertrophy of the kidney was highlighted by increased atrial natriuretic peptide 
(ANP) and brain natriuretic peptide (BNP) gene expression. These changes also correlated with 
increased TGFβ1 activity, gene expression in the left kidney and elevated active TGFβ1 in 
plasma of T1DM rats compared to control. The results clearly demonstrated that TIDM could 
elicit severe structural changes and alteration in biochemical markers (remodeling) in the 
kidney leading to diabetic nephropathy (DN). 
Key words: Diabetes-induced nephropathy, Apoptosis, fibrosis, Gene expression, Type 1 
diabetes, Transforming growth factor β1 (TGFβ1). 
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Introduction 
Diabetes-induced nephropathy (DN) is a pathological condition that can lead to cardiovascular 
failure resulting in death of diabetic patients [1]. It is well established that the chronic exposure 
of the kidney to hyperglycemic conditions favours the development of extensive structural 
damage [2]. DN is a micro-vascular complication leading to kidney dysfunction and end-stage 
renal disease (ESRD) [3]. The characteristics of DN include renal glomerular hypertrophy, 
basement membrane thickening, and fibrosis due to accumulation of ECM proteins and 
regulators [2,4]. Clinical features include proteinuria, albuminuria, and progressive glomerular 
dysfunction [5]. 
DN does not develop in the absence of HG, even in the presence of a genetic predisposition [6]. 
Nevertheless, HG is a crucial factor in the development of DN because of its effects on 
glomerular and mesangial cells, but alone it is not causative. Mesangial cells are crucial for 
maintenance of glomerular capillary structure and for the modulation of glomerular filtration 
via smooth-muscle activity [6]. HG is associated with an increase in mesangial cell proliferation 
and hypertrophy, as well as increased matrix production and basement membrane thickening. 
Several in vitro studies have demonstrated that HG is associated with increased mesangial cell 
matrix production and mesangial cell apoptosis [7]. One mechanism whereby HG can elicit 
unfavourable remodelling changes is via the activation of the pro-fibrotic cytokine TGFβ1. This 
concept is reinforced by previous experimental and clinical studies highlighting the functional 
linkage of HG-stimulated elevations in protein synthesis, in particular of ECM proteins with 
increased TGFβ1 signaling in the kidney [8]. Additionally, the role of TGFβ1 in DN has been 
highlighted in resultant increases in renal mesangial cells, kidney hypertrophy and cell survival 
[9]. TGFβ1 plays a major role in glomerular alteration in diabetic sclerosis via induction in 
transient actin cytoskeleton disassembly in mesangial cells, high production of fibronectin, 
collagen types I and IV, and mesangial cell hypertrophy. Thus, TGFβ1 may be considered as an 
important therapeutic target in DN.  
The present study was specifically designed to investigate the duration of T1DM on the kidney 
employing animals induced with T1DM for 2 and 4 months compared to many previous studies 
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that only investigated short- term effect of T1DM. In addition, the study attempted to ascertain 
whether structural remodelling in the kidney follows a similar pattern as myocardial matrix 
remodelling during diabetes for comparison.  
Methods 
Ethical Clearance:  The project obtained relevant clearance from the Animal Ethics Committees 
at University of Central Lancashire, UK, University of Nebraska Medical Center, Omaha, NE, USA 
and College of Medicine & Health Sciences, United Arab Emirates University, UAE. All 
procedures were in confirmation with the ‘UK Animals (Scientific Procedures) Act 1986’. 
Animals were housed in groups (1 or 2 in 1 cage) under institutional regulations at standard 
animal housing conditions. Animals were kept at an average room temperature of 24˚C, a 
relative humidity of 50% and a 12-hour day and night cycle. All rats were allowed unlimited 
access to water and commercial chow (unless indicated). All rats were regularly monitored 
throughout the experimental period for any signs of suffering or disease.  
Induction of Diabetes: This study employed 24 young adult male Wistar rats, 5-6 weeks old. 
The rats were divided into two groups of 12 each. One group was rendered diabetic by a single 
intraperitoneal injection (i.p.) of streptozotocin (STZ) (Sigma-0130) (60 mg kg-1 body weight) 
dissolved in citrate acid buffer (0.1 M citric acid, 0.1 M sodium citrate in distilled water, pH 4.5). 
Control animals received an equal volume (0.3 ml) of the citrate buffer alone. All rats were 
caged separately and fed routinely on a normal diet and water until after 2 months or 4 months 
of diabetes, when they were humanely killed for experimentations.  DM was confirmed 4-5 
days following STZ injection and on the day, prior to killing the rats, using a glucose meter (One 
Touch II glucose meter, Lifescan inc). 
Sample collection: Wistar rats were humanely killed by a blow to the head followed by cervical 
dislocation and the left kidney rapidly removed by mid-abdominal incision. Blood samples were 
taken directly from the heart by cardiac puncture. Following the removal of the kidney, it was 
blotted dry, weighed and either frozen in liquid N2 for protein assay/gene expression and 
stored at -80⁰C or processed for light/electron microscopy. For all animals, body weight and 
5 
 
kidney weight were measured immediately after isolation and non-fasting blood glucose was 
measured prior to experiments.  
Histological studies 
Tissues were processed for histological examination according to previously described 
techniques [10-11]. Briefly, kidney tissue samples were fixed in 10% formalin and dehydrated in 
alcohol series for specific time limits. Paraffin-embedded samples were sectioned at 4 µm using 
HM325 microtome, deparaffinized, rehydrated and stained with hematoxylin and eosin (H&E) 
for general examination and with Masson’s trichrome for the determination of ECM deposition 
according to previously established methods [10-11]. Morphometry was performed by digital 
image analysis using a PC digital image camera (Digital Sight DS-5M, Nikon Corp, Japan) 
mounted on an Axiolab Zeiss light microscope (Carl Zeiss Corp, Germany) with a 40X objective. 
Extent of ECM proliferation in the LV and Kidney was assessed using Image J software (National 
Institutes of Health, Bethesda, MD, USA; http://www.nih) and colour segmentation plugin was 
applied to calculate the percentage of interstitial fibrosis present in the Masson’s trichrome 
stained kidney sections. Image J was programmed to identify shades of a specific colour (green 
for collagen) on the stained sections. Approximately, 30-40 selected fields in each group were 
included in the analysis.  
 
 Immuno-histochemistry 
The activity of caspase-3 as a primary effector of kidney tissue apoptosis was measured using a 
commercially available caspase-3 detection kit following the manufacturers’ instructions 
(Signal-Stain Apoptosis (Cleaved Caspase-3) IHC detection kit, Cell Signaling Technology, 12692). 
Briefly, paraffin-embedded sections were deparaffinised a series of alcohol before antigen 
retrieval. Sections were then blocked with 1x TBST/5% normal goat serum and incubated for 1 
hour at room temperature. Sections were incubated over night at 4˚C with polyclonal rabbit 
anti-active caspase 3 antibody diluted in antibody diluent (1:500) supplied within the kit. 30 µl 
of chromagen concentrate was added to 1 ml of Signal Stain DAB Diluent, which was then 
applied to each section and monitored closely for acceptable staining intensity (red-brown) 
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monitored by light microscopy. A semi-quantitative analysis of the apoptotic cells that was on 
average of 30-40 LV groups, defined as caspase-3 positive cells/area (mm2) were obtained using 
Image J. Photomicrographs were imaged at X400.  
 Electron Microscopy 
Randomly selected semi-thin sections, were cut with glass knives and stained with Toluidine 
blue for examination by light microscopy in order to exclude abnormal tissues from 
ultrastructural studies. Thereafter, semi-thin sections were stained with methylene blue and 
examined in the light microscope to select appropriate areas for the preparation of ultrathin 
sections. Ultrathin sections were cut with a diamond knife (DuPont) on LKB III ultratome and 
picked up on mesh copper grids. Sections were carefully stained with saturated uranyl acetate 
solution in 50 percent ethanol for 15 min followed by lead citrate solution for two min. A JEM 
1010 electron microscope was used to examine the ultrathin sections at an accelerating voltage 
of 60 kV. Subsequently, electron micrographs were printed on 8 x 10 inch photographic paper 
at 7,000 X and 14,000 X magnifications.  
mRNA quantification by Quantitative Reverse transcriptase Polymerase chain reaction: mRNA 
isolation and generation of cDNA 
A two-step SYBR green I RT-PCR protocol was used to quantify mRNA expression of numerous 
target genes in ‘real time’ RTqPCR assays. The primer sequences, experimental conditions, 
design and techniques detailed below had previously been validated [13]. Briefly, frozen kidney 
samples were cut into 10 µm sections using a cryostat, making sure the samples do not thaw. 
Total RNA was isolated from sections using Qiagen muscle RNA extraction procedure and 
manufacturer’s instructions (Qiagen, Hilden, Germany). Briefly, 10 µl of β-mercaptoethanol was 
added to 1 ml of ‘RLT’ buffer provided and a stock of carrier RNA was prepared. Samples were 
homogenized and a volume of 5 µl of proteinase K was then added to digest proteins in tissue. 
A second elution gave a final volume of approximately 90 µl that was left to precipitate 
overnight at -20˚C followed by centrigugation, and resulting RNA was ethanol precipitated and 
pellets were dissolved in 10 µl, RNAse free water. Thereafter, the concentration and purity of 
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RNA samples was measured at A260 and the ratio of absorbance at 260 and 280 nm with a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Techologies, USA).  
A volume of 10 µl of the RT/buffer master mix was added while samples were on ice. Samples 
were then incubated at 25°C for 10 min in the PCR machine, for first priming, 50°C for 50 min, 
for further synthesis and 85°C for 15 min, to stop the reaction. Aliquots of neat cDNA were 
diluted (2 µl into 18 µl H2O) giving a 1:10 ratio for direct use in qPCR. 
QPCR  
Gene expression analyses were performed by reverse transcription and qPCR. RTqPCR was 
achieved using an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster, 
USA). The size of QPCR products and specificity of primers were tested in the laboratory 
previously by running samples on 2 % agarose gels containing ethidium bromide and visualized 
by UV light. For this study commercially available primers were utilized which gave amplicons of 
similar size. The reaction mixture consisted of 1 μl of cDNA, 1x Qiagen assay, 1x SYBR Green 
Master Mix (Applied Biosystems, 4367659) and the final volume of 10 μl was made up with 
DNAse-free water.  
Gene expression was analyzed using SDS 2.1.1 software (Applied Biosystems) by a double 
standardization method known as the modified 2-ΔΔCt that was adjust for PCR efficiency 
differences [14]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA 
were analyzed to determine the housekeeping gene whose amplification efficiency is equal to 
other PCR targets of this study. Ratios relative to the calibrator were determined based on the 
respective delta cycle tresholds. Expression levels were articulated as value of mRNA 
abundance relative to average GAPDH content.  
Transforming growth factor β1 Immunoassay  
Protein extraction - Left kidney samples from STZ-induced T1DM rats for 2 and 4 months and 
Wistar age-matched control animals were homogenized in in homogenization buffer, pH 7.4 as 
recommended by ELIZA kit manufacturers. Sample homogenate was sonicated and centrifuged 
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at 14,000 g for 1 min at 4 ˚C. The supernatant was collected and aliquoted into tubes and 
further assayed for protein concentration or stored at -80 ˚C.  
Modified Lowry protein assay - Protein concentrations in tissue homogenates of the kidney 
were assayed employing the modified Lowry method previously described [14] and a 
microplate reader (Micro Quant, Biotech Instruments) was used for analysis. The linearity range 
for protein detection was given as 1-1,500 µg/ml.    
Total and active Transforming growth factor β1 detection by Enzyme-Linked ImmunoSorbant 
Assay (ELIZA) - Total and biologically active TGF1 protein in serum and from frozen samples 
was measured using an enzyme-linked immunosorbent assay (ELISA) kit (TGF1 Emax 
ImmunoAssay System, Promega, USA) and manufacturer’s instructions.  
Detection of endogenous TGFβ1 in plasma, LV and kidney homogenates (extracted as 
mentioned above) from aged matched control and STZ-induced and GK subgroups were 
achieved using manufacturer’s protocol.  
Sample preparation was achieved by dividing plasma and kidney homogenates in 2 equal 
fractions to assay for total and active TGFβ1. A volume of 100 µl of either acid treated or 
naturally processed samples were added to the coated plate and incubated for 90 minutes at 
room temperature with shaking (500±100 rpm). Samples were diluted in buffer prepared 
according to manufacturer protocol. After washing, the specifically bound polyclonal antibody 
was detected by diluting 10 µl stock Anti-TGFβ1 pAb in 10 ml of Sample 1X buffer (1:1000). A 
volume of 100 µl of this was pipetted in each well and incubated for 2 hours at room 
temperature with shaking (500±100 rpm). Samples were incubated with 100 µl of TMB One 
Solution (chromagen substrate) for 15 minutes at room temperature, which produced a blue 
colour in the wells. The reaction was stopped using 100 µl of 1 N HCl, which changed the colour 
to yellow and was measured at 450 nm using a microplate reader (Anthos Hill, Biochrome Ltd, 
UK). Samples were analyzed in duplicate and the results were obtained by extrapolation from 
the TGFβ1 standard curve and expressed as ratio of Active: Total TGFβ1 for plasma samples and 
pg/mg of total protein for LV and kidney homogenates.     
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Statistical analysis 
 Quantitative data acquired from these experiments were statistically analyzed using different 
statistical tests. Mean (±SEM) data were plotted as graphs with n=3-6 different experiments. 
Statistical significance of differences between age-matched control and STZ-induced diabetic 
data were compared by Independent samples Student’s t-test using IBM SPSS statistics 22 
software (SPSS Inc., Chicago, IL, USA). Unless stated otherwise, statistical comparisons were 
performed using one-way ANOVA followed by Bonferroni corrected t-tests for multiple 
comparisons. A value of p<0.05 was taken as statistically significant and values <0.01 were 
taken as highly significant.  
 Results 
 Characteristic evaluation of the experimental model 
General characteristics of the STZ-treated T1DM rats and age-matched Wistar control are 
shown in Table 1. The results show that diabetes can significantly (p<0.05) reduce blood glucose 
level and body weights at 2 and 4 months compared to the respective age-matched controls. In 
contrast, T1DN significantly (p<0.05) increases kidney weight and kidney to body weight ratio 
compared to the respective controls. Changes in these different parameters were more severe 
following 4 month of T1DM compared to 2 months.   
Histopathology of the Kidneys after 2 and 4 months of STZ-treatment 
Figure 1 shows the histopathology of the left kidney at 2 and 4 months after STZ-induction 
compared to age-matched controls. Kidney optical analysis using the H & E stain by light 
microscopy revealed general disorganized architecture of the kidney characterized by 
expansion in glomerular borders, tubular atrophy and increased vacuolization of renal tubular 
epithelial cells in the STZ-induced diabetic group. In contrast, the control groups revealed 
organized intact glomeruli, Bowman’s capsule and tubular structure.  
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Table 1: General characteristics of T1DM and control rats. Data are shown as the Mean 
(±S.E.M), *p<0.05 **p<0.01, unpaired Student’s t-test. Numbers in bracket indicate number of 
animals used for experiments. 
 
Examination of the glomerular basement membrane   
Figure 2 shows glomerular basement membrane examination, highlighted by Periodic Acid 
Schiff (PAS) stained sections in the left kidney at 2 and 4 months after STZ-induction compared 
to age matched controls. Light microscopy revealed thickened glomerular basement 
membranes in both STZ-treated groups compared to age-matched control groups. Increased 
mesengial expansion is clearly visible in both groups as the earliest morphological change in 
diabetic nephropathy due to increased deposition of the mesangial matrix together with a mild 
increase in mesangial cellularity, and mesangial cells hypertrophy. 
 
Animals Fasting 
Blood 
Glucose 
(mg/dl) 
Body Weight 
(g) 
Kidney weight 
(g) 
Kidney Weight/Body Weight 
ratio (g/100g body weight) 
Control (n=6)             
2 months 
98±3.79 343±9.99 3.25±0.12 0.94±0.01 
Diabetic (n=6)             
2 months 
443±12.2** 270±5.78** 4.22±0.13** 1.56±0.02** 
Control (n=8)             
4 months 
97±3.04 378±10.63 3.08±0.13 0.82±0.01 
Diabetic (n=8)            
4 months 
446±18.8** 221±13.02** 4.45±0.16** 2.01±0.03** 
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Figure 1: Kidney pathology Representative light photomicrographs detailing kidney 
histopathology in H & E stained kidney sections at 2 and 4 months of STZ-induced diabetes and 
age-matched controls. General glomeruli are intact and organized in structure. Original 
magnification X400. Photomicrographs are typical of 20-25 fields/per group consisting of 6-9 
animals per group. Scale bar in the right hand corner is 20 µm and for all micrographs. D: Distal 
tubulus, P: Proximal tubulus, G: Glomerulus, BC: Bowman’s capsule, Tailed arrow: expanded g 
lomerulus borders in DM group, Block arrow: RBC that make statis in glomerulus and 
interstisium, Diamond; clear cells. 
 
 
 
.   
 
 
 
 
Figure 2: Glomerular basement membrane:  Representative light micrographs of PAS stained 
kidney sections from 2 and 4 months after STZ-treatment. Glomerular basement membrane is 
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seen to be increased in STZ-treated kidneys in comparison to age-matched controls. Original 
Magnification X400, Photomicrographs are typical of 35-47 fields/experimental groups 
consisting of 6-9 animals per group. Scale bar indicates 20 µm. D; Distal tubulus, P; Proximal 
tubulus, Tailed arrow; thickened basement membrane of glomerulus, Block arrow; increased 
Bowman’s space, Diamond; clear cells of tubulus Triangle; Dilated tubulus.   
Ultrastructural study of the kidneys after 2 and 4 months of STZ-treatment  
Figure 3 shows electron microscopic images of the left kidney at 2 (A) and 4 (B) months after 
STZ-induction compared to age-matched controls. The image shows ultrastructural abnormality 
in diabetic nephropathy as seen as diffused thickening of the GBM. In addition, a variable 
degree of mesangial expansion by extracellular matrix deposition and increased mesangial 
cellularity is also present in the diabetic kidney of both groups. A reduction in podocyte number 
(podocytopenia), along with a reduced podocyte per glomerulus ratio can also be seen in both 
groups after STZ-induction. Diffuse foot process effacement and podocyte detachments are 
another hallmark of DN and they are visible in both STZ-treated groups. Figure 2C shows 
quantitative assessment of GBM width using Image J analysis tool. The data revealed significant 
(p< 0.05) increases at 2 months (510±1.35 vs. 330±1.15 µm) and 4 months after STZ-treatment 
(540±1.50 vs. 348±1.15 µm) compared to age-matched controls.  
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Figure 3: Kidney Ultrastructure: Representative TEM electron micrographs showing increased 
mesangial matrix and glomerular basement membrane (GBM) together with increased 
detachment of podocytes in the kidneys from 2 and 4 months after STZ-treatment (A) and 
quantitative assessment of GBM (nm) using Image J analysis tool (B). Original magnification X 
14,000. Electron micrographs are representative of 35-45 photomicrographs studied from 5-6 
animals per group. Scale bar in the lower right indicates 1µm; MM; Mesangial Matrix, Block 
arrow; Thick GBM, NP; Normal Podocyte, Chevron; Podocyte detachment. Data are MeanSEM, 
*P< 0.05, One-way ANOVA followed by Bonferroni corrected t-tests for multiple comparisons. 
 
Kidney fibrosis after 2 and 4 months of STZ-treatment 
Figure 4 shows the results from light microscopy photomicrographs of Masson’s Trichrome 
stained sections in the left kidney after STZ-induction compared to age-matched controls 
following 2 (A) and 4 months (B). STZ-treated rats demonstrated significantly increased ECM 
deposition in both glomerulus and tubulus regions. Figure 4C shows quantitative analysis of 
fibrosis in STZ-treated rats and the data revealed significantly greater glomerular area coverage 
as compared to age-matched controls occupying at 2 months (5.89±0.51% vs. 2.41±0.44%; 
p<0.05) and 4 months (7.66±0.53% vs. 3.36±0.46%; p<0.01 post STZ-treatment. These changes 
were significantly (p<0.05) different between 2 and 4 months of STZ-treatment time indicating 
the severity of the diabetes in the kidney. 
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Figure 4: ECC deposition in the kidney::Representative light micrographs of Masson’s 
Trichrome stained myocardial sections from 2 months after STZ-treatment (A) and 4 months 
after STZ-treatment (B) and quantitative assessment of interstitial fibrosis using Image J analysis 
tool (C). Original Magnification X400, Photomicrographs are typical of 35-47 fields/experimental 
group consisting of 6-9 animals per group. Scale bar indicates 10 µm. Data are MeanSEM, *p< 
0.05, **p< 0.01 One-way ANOVA followed by Bonferroni corrected t-tests for multiple 
comparisons.   
Apoptosis in the kidneys after 2 and 4 months of STZ-treatment 
Figure 5 shows a significant (p<0.05) increase in the immune-reactivity of cleaved (active) 
caspase-3 within the left kidney of STZ-treated diabetic rats compared to age-matched controls 
at (A) 2 months (8.96±0.89 vs. 1.89±0.39) positive cells/mm2 (p<0.05) and (B) 4 months 
(9.66±1.00 vs 2.49±0.50) positive cells/mm2 after STZ-treatment. Figure 5C shows quantitative 
analysis of positive caspase-containing cells in the kidney of age- matched control and diabetic 
rats. This increase was significant (p<0.05) in diabetic kidney compared to control. 
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Figure 5: Kidney Apoptosis: Active Caspase-3 positive cells (brown staining) in the kidneys from 
2 months after STZ-treatment (A) and 4 months after STZ-treatment (B) and quantitative 
assessment of immune-reactivity using Image J (C). Photomicrographs are typical of 15-20 
fields/experimental groups consisting of 5-6 animals per group. Diamond; clear cells of tubulus, 
Block arrow; Thickened basement membrane and small glomerular size. Scale bar indicates 20 
µm and for all photomicrographs. Data are MeanSEM, *p< 0.05, One-way ANOVA followed by 
Bonferroni corrected t-tests for multiple comparisons. 
 
Molecular events underlying structural remodeling in the kidneys  
Gene expression for ECM components 
Figure 6 represents gene expression of the ECM components, collagen 1α, collagen 3α, 
fibronectin and elastin quantified using qRT-PCR. The data revealed a significant (p<0.01) 
increase of collagen 1α after 2 months (0.89±0.14 vs. 0.53±0.10 ratio units) and 4 months 
(1.23±0.13 vs. 0.58±0.11 ratio units) of STZ-treatment (figure 6A). Similarly, there was a 
significant (p<0.05) increase in collagen 3α after 2 months (1.00±0.12 vs.0.61±0.09) and 4 
months (1.45±0.13 vs. 0.68±0.07 ratio units) (figure 6B) in of STZ-induced diabetes compared to 
age-matched control. Both type of collagens showed significant (p<0.05) differences between 
the two age- groups indicating that collagen expressions are changed over time possibly due to 
the duration of diabetes. Fibronectin (figure 6C) and elastin (Figure 6D) were significantly 
increased at 2 months (fibronectin; 1.26±0.14 vs. 0.92±0.07 ratio units), (elastin; 0.98±0.13 vs. 
0.55±0.05 ratio units) and 4 months (fibronectin; 1.59±0.11 vs. 0.92±0.07 ratio units), (elastin; 
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1.09±0.12 vs. 0.59±0.08 ratio units) after STZ-induction compared to age-matched control.  
However, only fibronectin revealed an adult vs young adult effect that was significantly (p<0.05) 
evident. Furthermore, these changes were accompanied by divergent alterations in ECM 
regulators.  
Figure 7 shows the gene expression of ECM regulators MMP2, MMP9, TIMP4, CTGF, connexin 
43, integrin 5α and vimentin. Kidney mRNA gene expression for MMP2 (Figure 7A) revealed a 
significant (p<0.05) down regulation at 2 months (0.56±0.12 vs. 1.00±0.11 ratio units) and 4 
months (0.58±0.13 vs. 1.13±0.10 ratio units) after STZ-induction compared to age-matched 
control. On the other hand, MMP9 (Figure 7B) was significantly (p<0.05) up-regulated at 2 
months (1.16±0.11 vs. 0.86±0.02 ratio units) and 4 months (1.31±0.12 vs. 0.91±0.10 ratio units) 
after STZ-induction compared to age-matched controls. Interestingly, endogenous MMP tissue 
inhibitor TIMP4 (Figure 7C) was up regulated at 2 months (1.00±0.12 vs. 0.67±0.06 ratio units) 
and 4 months (1.32±0.11 vs. 0.93±0.05 ratio units) after STZ-induction compared to age-
matched control and this difference was significantly (p<0.05)  evident between the two age 
groups. mRNA gene expression level for CTGF (Figure 7D) was significantly p<0.05)  increased at 
2 months (1.11±0.14 vs. 0.57±0.04 ratio units) and 4 months (1.23±0.15 vs. 0.79±0.08 ratio 
units) after STZ-induction compared to age-matched controls. Additionally, a significant 
(p<0.05) down-regulation in gap junction protein Cx43 (Figure 7E) was evident in the STZ-
induced diabetic rat kidney after 2 months (0.89±0.12 vs. 1.28±0.06 ratio units) and at 4 months 
(p<0.01) (0.45±0.14 vs. 1.39±0.09 ratio units) of STZ-induction compared to age-matched 
control and this difference was significantly (p<0.05) evident between the two age groups. 
Additionally, mRNA level of Integrin 5α (Figure 7F) was significantly (p<0.05) increased at 2 
months (1.08±0.13 vs. 0.49±0.06 ratio units) and 4 months (1.19±0.15 vs. 0.55±0.09 ratio units) 
after STZ-induction compared to age-matched control. Integrin 1α was also studied, but 
remained unaffected by the disease. Finally, mRNA level of vimentin (Figure 7G) was 
significantly (p<0.05) up-regulated at 2 months (1.08±0.13 vs. 0.49±0.06 ratio units) and 4 
months (1.19±0.15 vs. 0.55±0.09 ratio units) after STZ-induction compared to age-matched 
control. Taken together, gene expression profile of ECM components in the kidneys revealed 
marked changes that were accompanied by parallel alterations in ECM regulating agents 
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(MMP2 and MMP9) and tissue inhibitor (TIMP4), gap junction proteins and vimentin 
expression, .An imbalance in these expressions could lead to abnormal ECM deposition which 
remains as one of the hallmarks of DN. 
 
ECM Components 
 
 
Figure 6: Gene expression of ECM component:  Summarized data showing gene expression for 
ECM components Collagen 1 (A), Collagen 3 (B), Fibronectin (C) and Elastin (D) in STZ-treated 
and age-matched controls at 2 and 4 months post STZ-treatment. Results are representative of 
8 animals/per group conducted in triplicates. RT-PCR amplification was normalised to that of 
GAPDH. Data are expressed as mean ± SEM. Lines over bars indicate significance * p<0.05, One-
way ANOVA followed by Bonferroni corrected t-tests for multiple comparisons. 
 
 
 
 
 
 
 
 
 
Figure 7: Gene expression of ECM regulatory components: Summarized quantitative data 
showing gene expression for ECM regulators MMP2 (A), MMP9 (B), TIMP4 (C), CTGF (D), 
Connexin 43 (E), Integrin 5α  (F), and Vimentin (G) in STZ-treated and age-matched controls at 2 
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and 4 months post STZ-treatment. Results are representative of 8 animals/per group conducted 
in triplicate. RT-PCR amplification was normalised to that of GAPDH. Data are expressed as 
mean±SEM. Lines over bars with asterisk indicate significance * p<0.05, ** p<0.01, One-way 
ANOVA followed by Bonferroni corrected t-tests for multiple comparisons. 
 
 Assessment of hypertrophy in kidneys 
The hypertrophic biomarkers ANP and BNP were assessed in STZ-induced and age-matched 
controls at 2 and 4 months post STZ-treatment. Figure 8 shows the gene expression analysis for 
ANP and BNP. The results revealed that ANP was significantly p<0.05) up-regulated at 2 months 
(1.55±0.16 vs. 0.56±0.09 ratio units) and 4 months (2.50±0.14 vs. 0.67±0.06 ratio units) after 
STZ-induction compared to age-matched control. There was a significant (p<0.05) difference 
between the two age groups, indicating a diabetes-induced age-related effect. On the other 
hand, BNP was significantly (p<0.05) up-regulated at 4 months (0.89±0.12 vs. 0.55±0.09 ratio 
units) after STZ-induction compared to age-matched controls. However, no significance 
(p<0.05) was observed at 2 months (0.55±0.13 vs. 0.49±0.66 ratio units) after STZ-induction. 
 
 
 
 
Figure 8: Gene expression for ANP and BNP biomarkers: Summarized quantitative data 
showing ANP (A), and BNP (B) gene expression in STZ-treated and age-matched controls at 2 
and 4 months post STZ-treatment. Results are representative of 8 animals/per group conducted 
in triplicates. RT-PCR amplification was normalized to that of GAPDH. Data are expressed as 
mean±SEM. Lines over bars with asterisk indicate significance * p<0.05, ** p<0.01, One-way 
ANOVA followed by Bonferroni corrected t-tests for multiple comparisons.  
 
TGFβ1 in plasma and kidney after 2 and 4 months of STZ-treatment 
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Figure 9 shows plasma level as well as total, active and gene expression for TGFβ1 in the kidney. 
The results show that  TGFβ1 was significantly (p< 0.05) increased in plasma after 2 months 
(2.72±0.20 vs. 1.15±0.04 ng/ml) of STZ-induced diabetes compared to control whereas no 
significant differences were observed after 4 months (2.36±0.06 vs. 2.18±0.07 ng/ml) of STZ-
treatment (Figure 9A). Total TGFβ1 levels were significantly (p<0.05) increased in STZ-induced 
diabetic kidney at 2 months (9.53±0.12 vs. 3.44±0.20 pg/mg of total protein) and 4 months 
(11.92±0.32 vs. 4.73±0.15 pg/mg of total protein) after STZ-treatment compared to age-
matched control and this significance was apparent between the two age groups (Figure 9B). 
Similarly, active TGFβ1 levels in kidneys were significantly (p<0.01) increased after 2 months 
(60.75±0.38 vs. 28.83±0.35 pg/mg of total protein) and 4 months (59.68±0.32 vs. 36.33±0.28 
pg/mg of total protein) of STZ-induction compared to age-matched control (Figure 9C). 
However, these differences were not significantly different between the two age groups. TGFβ1 
gene expression was also significantly (p<0.05) different between the two age groups (after 2 
months; (1.25±0.13 vs. 0.55±0.05) and after 4 months; (1.79±0.15 vs. 0.88±0.08) in STZ induced 
diabetic rat LV compared to age-matched control this significance was apparent between the 
two age groups (Figure 9D). 
 
Figure 9: Plasma level, total, active and gene expression of TGFβ1: Summarized quantitative 
data from ELIZA showing ratio of active : total TGFβ1 protein in plasma (A), total TGFβ1: total 
extracted kidney protein (B) and active TGFβ1: total extracted kidney protein (C) at 2 and 4 
months of STZ-treatment with age-matched control animals (n=3/group). mRNA gene 
expression of TGFβ1 (D) at 2 and 4 months of STZ-treatment with age-matched controls. The 
results of both ELIZA and qRT-PCR are representative of 3 individual experiments conducted in 
triplicate. RT-PCR amplification was normalized to that of GAPDH. Data are expressed as mean 
± SEM. Lines over bars indicate significance * p<0.05, ** p<0.01, One-way ANOVA followed by 
Bonferroni corrected t-tests for multiple comparisons.  
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Discussion  
In this study, the morphological and molecular consequences of HG-induced diabetes have 
been characterized in the left kidney of STZ-induced type 1 diabetics male rats compared to 
age-matched controls. The left kidney is slightly larger than that of right kidney and it is 
positioned slightly upper than the right kidney due to asymmetry within the abdominal cavity 
caused by the liver. In addition, its posterior surface is associated with the spleen, pancreas, 
stomach and other organs surrounding it. Male rats are normally employed in most diabetic 
studies in order to avoid any complications of other hormonal changes that may occur in 
females, but not in male animals. The discussion will now focus on the various measured 
parameters in this study. 
Firstly, the general characteristics of rats revealed significant decreases in body weight in STZ-
induced rats compared to the respective controls. In contrast, there were marked elevations in 
blood glucose levels, kidney weights and kidney weight to body weight ratios observed in the 
STZ-induced rat at 2 and 4 months after diabetes-induction compared to control.  The increase 
in kidney size is an indication of renal hypertrophy, which is the hallmark of DN [15-16]. This 
increase in size is primarily due to glomerular and tubular hypertrophy, although some low-
grade proliferations of glomerular cells are also present in the early stage of DN [16,17]. 
Glomerular hypertrophy is in part the result of glomerular cell hypertrophy and recent studies 
have suggested that the diabetic milieu per se, hemodynamic changes and local growth factors 
such as TGFβ1 and angiotensin II (ANG II) are mediators in the pathogenesis of glomerular cell 
hypertrophy [16]. The results of this study are consistent with previously published reports on 
renal hypertrophy [18]. Previous in vitro studies have reported that high glucose, TGFβ1 and 
ANG II are mediators of DN and they are closely linked with the Akt pathway [19]. Owing to 
these findings, the activity of Akt under diabetic conditions has been heavily investigated, but 
discrepancies remain, some have demonstrated an increase in Akt phosphorylation [19].  
The results of this study revealed marked elevations in gene expression levels for ANP and BNP, 
which are sensitive biomarkers for hypertrophy. The up-regulation in ANP and BNP levels in the 
left kidney at 2 and 4 months post STZ-induction compared to age-matched controls is 
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consistent with previous studies [20]. Therefore, monitoring of ANP and BNP can play an 
important role in the management of DN.  
Ultrastructure studies of the kidney in T1DM 
Ultrastructural analysis employed in this study revealed an increase in GBM thickness in the 
kidney from 2 and 4 months of STZ-induced diabetes compared to age-matched control 
animals. Data from the literature suggest that GBM thickening is a characteristic of early change 
in T1DM [21]  and T2DM-induced DN [22] and it increases with the disease duration [23]. GBM 
thickening is a consequence of ECM accumulation, with increased deposition of normal ECM 
components together with altered expression of the regulators of EM, similar to the findings of 
this study (Figure 6). Another hallmark feature of DN is the derangement of the architecture of 
podocytes and glomerular endothelial cells which participate in initiation and progression of 
nephropathy resulting in significant effect on the function of the kidney [24]. Podocyte 
detachment (PD), (Figure 5) and structural changes in DN have previously been described in 
T1DM with similar results to the findings of this study [24-25]. 
Apoptosis in the diabetic kidney 
Increased apoptosis mediated by caspase-3 immuno-reactivity has been highlighted in this 
study. At both 2 and 4 months after TIDM induction, the rat kidney was infiltrated with 
increased apoptotic cells compared to respective age-matched control groups. Apoptosis has 
been documented in the time course of various renal diseases and more frequently in DN [26]. 
Cell death by apoptosis is believed to be involved in the process of mesangial cell loss in the late 
stage of DN [27]. In addition, apoptosis is considered to be one of the underlying causes of 
podocyte loss, which contributes to the development of albuminuria in DN [26]. STZ-induced 
diabetic rats at 2 and 4 months displayed signs of tubular, as well as, interstitial apoptosis 
compared to respective control groups and these results are in correlation with previously 
published study in STZ-diabetic rat kidney [28]. A previous study has shown that this damaging 
due to T1DM can be reversed by insulin therapy [28]. Moreover, Ang II type 1 (AT1) and type 2 
(AT2) Ang II receptor blockade can reduce apoptosis in the diabetic kidney indicating 
therapeutic relevance in the treatment of DN [29]. 
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Role of TGFβ1 in kidney remodeling 
The present study supports previous observations that TGFβ1 is upregulated in the diabetic 
kidney and that this upregulation is associated with glomerulosclerosis and tubule-interstitial 
fibrosis [30]. Numerous studies have demonstrated that TGFβ1 promotes renal cell growth, 
stimulates synthesis of key ECM proteins including, type I and type II collagen, laminin and 
fibronectin and inhibits ECM degradation by decreasing the activity of MMPs [15]. These results 
in the literature are consistent with findings from this study which showed marked elevations in 
ECM components (Col 1α, Col 3α, elastin and fibronectin) together with glomeru-sclerosis in 
the STZ-induced diabetic kidney at 2 and 4 months post STZ-induction compared to age-
matched control animals. 
TGFβ1 plays an important role in the pathophysiology of renal disease, including DN. 
Furthermore, the present study showed an overall increase in TGFβ1 activity in left kidney of 2 
and 4 months after STZ-induction compared to respective age-matched controls. Elevated 
TGFβ1 activity was correlated with parallel findings of increased TGFβ1 gene expression that is 
consistent with previous findings with correlations to fibrosis in animals [31] and in humans 
[15]. A previous study reported that TGFβ1 is over expressed in glomerular mesangial cells, 
proximal and distal tubules in the STZ-induced diabetic rat after 9 weeks of diabetes [32]. These 
authors demonstrated that supplementation with 17β-estradiol (E2) for 8 weeks following a 9-
week duration of diabetes attenuates TGFβ1 protein expression, suggesting that one of the 
mechanisms by which E2 exerts its reno-protective effects in the diabetic kidney is by regulating 
the expression of locally active cytokines, such as TGFβ1.  
The results of this study have also revealed significant increases in the gene expression of CTGF, 
another pro-sclerotic cytokine, in the kidney of T1DM rats compared to the respective controls 
CTGF has been shown to be involved in both the early and later stages of DN. CTGF expression 
is seen to be increased in experimental diabetic glomerulosclerosis [33]. Elevated CTGF levels in 
glomeruli of NOD mice appear to correlate with the duration of diabetes [34]. Elevated CTGF 
expression has also been detected in human DN [33]. Gromerular CTGF levels have been found 
23 
 
to be elevated in diabetic patients with micro-albuminuria as well as overt nephropathy [35]. 
Several in vitro studies have shown that CTGF is induced in renal cells by high glucose and AGE 
[36], as well as ROS [37], which they generate. CTGF is one of the TGFβ1 inducible immediate 
early genes and has shown to be induced by TGFβ1 [38CTGF is a crucial mediator for TGFβ1 
stimulated matrix protein expression. Additionally, CTGF has been shown to mediate TGFβ1 
induced increases in fibronectin and collagen type I [39]. Collectively, these observations are 
consistent with the findings of the present study and correlate with the fact that although all 
these factors likely interact in the pathogenesis of DN, the driving force behind the cytokine 
expression is most likely to be HG, either directly or indirectly.  
Role of metalloproteinases in T1DM 
The results of this study have shown reciprocal changes in MMP2 and MMP9. The level of 
MMP2 decreased significantly in the kidney of diabetic rats compared to controls, whereas 
MMP9 and TIMP4 increased significantly in T1DM compared to control. MMPs are major 
determinants of extracellular matrix degradation and turnover in the glomerulus. Hence, the 
changes in either MMP expression or activity can influence intra-renal ECM composition [40]. 
Renal hypertrophy is prognostic of the development of micro-albuminuria in type 1 DM [41]. 
Since abnormal extracellular matrix deposition is the hallmark of diabetic nephropathy, it is to 
be expected that either altered MMP expression or activation also contributes to diabetic 
nephropathy, and specifically to the onset of this characteristic renal hypertrophy.  
 
It has been reported that MMP9 was dramatically increased in the glomeruli of diabetic mice, 
and MMP9 deficiency attenuates diabetic nephropathy by modulation of podocyte function 
and dedifferentiation. Collectively, these results suggest MMP9 can play a role in the 
development of diabetic nephropathy [42]. Elevated MMP9 levels have strong correlations with 
age, body mass index (BMI) and HbA1c levels, as well as progression of diabetes [43]  
 Previous studies in humans have also found circulating TIMP1, TIMP4 and MMP2 to be 
decreased in patients with DN [44]. Furthermore, Del Prete et al. [45] demonstrated a dramatic 
decrease in MMP2 gene expression in glomeruli of patients with T2DM. However, another 
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study showed that MMP2 protein and related-enzyme activity were up-regulated in kidneys of 
patients with diabetes, as assessed by Western blot analysis and ELISA methods [46].  
The MMPs have long been identified as critical mediators of ECM degradation and turnover, 
but increasing evidence suggests that they, in conjunction with TIMPs, play an important role in 
the progression of diabetic nephropathy. Additionally, TIMP4 is involved in suppressing the 
activity of MMP1, MMP2, MMP3, MMP7 and MMP9 [47].  
The present results revealed marked decreases in Cx43 levels of 2 and 4 months STZ-induced 
diabetic rat kidney compared to age-matched controls and this change was more severe with 
the duration of the diabetes. Previous studies in human kidney cells in culture have highlighted 
the possibility of a protective effect of Cx43 in preventing renal damage [48]. Specifically, 
studies in human collecting duct cell lines found that as glucose concentrations increased, there 
was a time-dependent increase in levels of Cx43 that is opposite to the observations made in 
the present study [48]. The increase in Cx43 and gap junctional communication correlated with 
functional acceleration of calcium transients between cells. Furthermore, levels of Cx43 have 
also been studied in human DN as a predictive marker of disease progression and severity [49]. 
Another study reported that down-regulation of Cx43 within podocytes was closely associated 
with disease progression in established DN and correlated with the degree of future decline in 
renal function [50]. Additionally, vimentin was found to be elevated in STZ-induced diabetic rat 
kidney at 2 and 4 months of STZ-induced DM. Vimentin is a major intermediate filament (IF) 
protein of the mesenchymal cells and is physiologically important as it shows dynamically 
altered expression patterns during different developmental stages [51].  
Major functions of vimentin involve the maintenance of cellular integrity and provide resistance 
against stress [52]. A number of studies have found the role of TGFβ1 in response element 
within the activated protein complex-1 region of the vimentin promoter to be involved in 
regulation of vimentin expression  [52]. Thus, the increased gene expression of vimentin may be 
closely related to the increased TGFβ1 activity observed in this study. Furthermore, this may 
depend on the duration of the diabetes since the expression of both TGFβ1 and vimentin 
increased at 4 month compared to 2 months.  
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Conclusion  
In conclusion, the results of this study clearly demonstrated that TIDM can elicit severe 
structural changes and remodelling of the kidney as revealed by the fibrosis, similar to that 
seen in the myocardium of diabetic rats [10-11]. These associated structural and biochemical 
alterations can lead to diabetic nephropathy (DN) and this in turn can be more severe 
depending on the duration of the diabetes.  
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